BioMedTracker will be offering numerous medical meeting conference planners through 2014 for purchase a la carte, or in a bundle of several select conferences. For more information on conference availability and pricing, please email BioMedTracker or call BioMedTracker Client Services at (858) 200- 2357. The European Society of Cardiology (ESC) 2014 Congress will be held in Barcelona, Spain from August 30-September 3, 2014.
Major presentations at this year's conference include details from LCZ696's (NVS) PARADIGM-HF positive outcomes trial in heart failure and Phase III data from PCSK9 inhibitor alirocumab (REGN, SNY), where an extension trial showed a reduction in major adverse cardiovascular events (MACE). One hot-line session will also have proof-of-concept results for TRO40303 (Trophos), a novel mitochondria pore modulator for acute myocardial infarction, but it has not been released whether results are positive or negative. We have assembled a full pre-meeting planner listing talks and posters. In addition to the above, we have highlighted various other presentations with some background and where available, results, including: Acute Coronary Syndrome and Coronary Artery Disease

• Ivabradine's (Servier, AMGN) SIGNIFY in stable CAD
• In ambulance treatment with Ticagrelor (AZN, MDCO; ATLANTIC study)
• Darapladib's (GSK) failed SOLID-TIMI 52.

Dyslipidemia

• Details on ISIS-APO(a)Rx's Phase I study

Stroke Prevention in Atrial Fibrillation

• First-in-man study of small molecule aripazine (Perosphere) to reverse factor X anti-coagulants
• X-VERT: rivaroxaban (JNJ, BAYRY) versus warfarin for early or late cardioversion
• Favorable effects of dabigatran on renal function (Boehringer)

Heart Failure

• Phase II results for SDF-1 (Juventas), plasmid stromal cell-derived factor 1

Pulmonary Arterial Hypertension

• One-year results from riociguat's (BAYRY, MRK) PATENT-2

Devices

• Vagal stimulation for heart failure (NECTAR-HF and ANTHEM-HF)
• Biventricular pacing for routine pacing indications (St. Jude)
• Stents: Orsiro biodegradable polymer (Biotronik), Cobra PzF (CeloNova), Bioresorbable PLLA/ACP scaffold (Vasotech)
• Value of treating non-culprit lesions with PCI during STEMI (CvLPRIT)
• One year results from Medtronic's renal denervation trial, SYMPLICITY HTN (6 months results were negative)

To download the full conference planner in PDF and Excel, click the link at the top of the page. For our disclosures, please read the BioMedTracker Research Standards.